The equivalent improvement was observed in NAFLD rats, which might be related to the decreased expression of liver forkhead box O1 (FOXO1) and its target genes such as phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), and other gluconeogenic genes [105]. Here, FOXO1 is linked to metabolic dysfunction-associated steatotic liver disease.